Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695005 | 0.79 | KDM4E (0.41) | KDM4EGAARAB9ASMN1; SMN2LMNA | |
| SCHEMBL20582831 | 0.79 | CYP19A1 (0.41) | GFERKDM4EGAARAB9ASMN1; SMN2 | |
| SCHEMBL5539570 | 0.79 | RAB9A (0.41) | KDM4ERAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL2092347 | 0.79 | AHR (0.46) | KDM4ENOTUMRAB9ACASP3KMT2A | |
| SCHEMBL315880 | 0.78 | PDPK1 (0.43) | KDM4ERAB9ASMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL8649872 | 0.78 | EPHB4 (0.40) | ADORA2AADORA1PTGS2 | |
| SCHEMBL7507911 | 0.77 | CYP19A1 (0.42) | NOTUMRAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL18952901 | 0.77 | APEX1 (0.34) | NOTUMKMT2AALDH1A1 | |
| SCHEMBL6026760 | 0.76 | NPC1 (0.44) | NOTUMGAARAB9ASMN1; SMN2LMNA | |
| SCHEMBL2750624 | 0.75 | RAB9A (0.38) | KDM4ENOTUMGAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247811-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-09-27 | — | — | EP | claimed |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | claimed |
| CN-116406359-A | Bicyclo [1.1.1] pentanes for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2023-07-07 | — | — | CN | claimed |
| WO-2022106375-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | claimed |
| CN-102008459-B | Antibacterial agents | BIOTA SCIENT MAN | 2013-05-29 | — | — | CN | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
| US-6767918-B2 | ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-07-27 | — | — | US | claimed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4247811-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-4221807-A | ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-09-09 | — | — | US | disclosed |
| US-4200652-A | ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-04-29 | — | — | US | disclosed |
| US-4141987-A | HYPOTENSIVE, ADRENERGIC BLOCKING AGENT | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-02-27 | — | — | US | disclosed |
| US-4115409-A | CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | GFER 1352/4885KDM4E 4854/4885NOTUM 3827/4885 |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP1B1, CYP7A1 | GFER 2336/4885KDM4E 3906/4885NOTUM 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.